Subhash Chaudhary, MD
Dr Subhash Chaudhary, is the Chief of the Division of Pediatric Infectious Diseases. He earned his medical degree from All India Institute of Medical Sciences, New Delhi, India. After completing residency in Pediatrics and fellowship in Pediatrics Infectious Diseases at St Jude Children research Hospital he has been at SIU School of Medicine. He is the Chairman of Infection Prevention and Control at St John’s Hospital. He served as Chairman of Pediatrics at Memorial Medical Center for 21 years. He has authored work on Pneumocystis Pneumonia and Group A Streptococcal infections in children.
- Cerexa P903-23. A Multicenter, Randomized, Observe-Blinded, Active-Controlled Study to evaluate the safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections
- Bayer QUIP Protocol 100201. “A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV oral therapy or purely IV therapy) or a non-quinolone antibiotic (either as oral suspension, oral tablets or sequential IV oral therapy or purely IV therapy) in the treatment of pediatric patients with infectious diagnoses.” Principal Investigator in Springfield. Expenses only (2000 – 2008)
- A case-control study of non-steroidal anti-inflammatory drug use as a risk factor for group A streptococcal necrotizing fascitis in children (A Multi-Center Study, conducted by The Slone Epidemiology Unit, Boston University School of Medicine in collaboration with The Childhood and Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention). Principal Investigator in Springfield. Expenses only (07/19/96-07/98)
- National enterococcus susceptibility surveillance study. (Multicenter Collaborative Study).
- Co-investigator (P.I. Ronald N. Jones, M.D., Iowa city, IA). Marion Merrell Dow, Inc., $1000 (July 92-Janaury 93).
- Treatment of gonococcal infections with intramuscular tropsectinomycin sulfate or ceftriaxone sodium. Co-investigator (P.I. Larry A. VonBehren, M.D.), UpJohn, Inc., $100,000 (March 89-March 90).
- A randomized study to compare the efficacy and safety of ceftazidime (Fortaz) and ceftazidime plus tobramycin in the treatment of febrile neutropenic children, Principal Investigator. Glaxo, Inc., $9500 (12/5/86-08/29/88).
- A comparative study of parenteral ampicillin/sulbactam versus ampicillin and chloramphenicol in the treatment of acute bacterial meningitis in infants and children. Principal Investigator. Pfizer Pharmaceuticals, $7500 (11/9/87-02/20/90).
- Open non-comparative study of ampicillin/sulbactam in the treatment of Epiglottitis in infants and children. Principal Investigator. Pfizer Pharmaceuticals, $2000 (11/9/87-02/20/90).
- Rifampin and penicillin for prevention of rheumatic fever. Principal Investigator. American Heart Association-Illinois Affiliate. $22,534/2 years (07/01/82-06/30/84).
- A clinical study of the effects of reduced dosage on the immunogenicity and adverse effects of Diphtheria-Tetanus-Pertussis (DTP) immunization. (Pilot project). Principal Investigator. Special Start-up Funds from the Associate Dean for Research, SIU School of Medicine. $1500 (10/18/82-06/30/84).
- Secretory and serologic responses to ribosomes and live cell vaccine of Haemophilus influenzae. Principal Investigator. Central Research Funds (CRC-2-40063-71), SIU School of Medicine $10,250/2 years (07/01/78-06/30/80).
- Comparative efficacy of cefaclor and TMP-SMX in infants and children with otitis media. Principal Investigator. Eli Lilly and Co. (EL-638) $14,400 (06/01/79-05/30/80).
- Systematic study of humoral immunity to Haemophilus influenzae in human beings. Principal Investigator. Central Research Funds (CRC-2-400634-71), SIU School of Medicine $4,480/2 years (07/01/80-06/30/82).
- Comparative efficacy of clindamycin vs. nafcillin/dicloxacillin in the treatment of acute staphylococcal osteomyelitis in Children. Infectious Disease Medical Research, The Upjohn Company, Kalamazoo, Michigan. Principal Investigator. $11,000.
- Immunity to Haemophilus and group B streptococcus infections. Principal Investigator. N.I.H. $102,570/4 years, $24,787/first year. Part of program project “Prevention of infectious diseases in infants.” R.P. Tewari (Program Director).
- Interaction of Streptococcus pyogenes with endothelial cells. American Heart Association-Illinois Affiliate, Principal Investigator